The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Abstract
The objective of this study was to review loss of response and need for adalimumab dose intensification in adult and pediatric patients with Crohn's disease. Studies were identified through the electronic databases of MEDLINE and the annual meetings of Digestive Disease Week, of the United European Gastroenterology Week, and of the American College of Gastroenterology and the European Crohn's and Colitis Organization meetings. Studies evaluating loss of efficacy and/or need for dose intensification were included. Thirty-nine studies were included. The mean percentage of loss of response to adalimumab among primary responders was 18.2% and the annual risk was 20.3% per patient-year. The mean percentage of patients who required dose intensification among primary responders to adalimumab was 37% and the annual risk was 24.8% per patient-year. When considering initial responders and patients with primary non-response, the mean percentage of patients who needed an adalimumab dose escalation was 21.4% and the annual risk was 24.4% per patient-year. Pooled analysis showed that dose escalation permitted response to be regained in 71.4% and remission in 39.9% of patients. Predictors for loss of response or dose escalation were male gender, current/former smoker status, family history of inflammatory bowel disease, isolated colonic disease, extra-intestinal manifestations, 80/40 mg induction therapy, longer disease duration, greater baseline Crohn's Disease Activity Index, concomitant corticosteroid use, no deep remission at week 12, low serum trough concentrations of adalimumab, previous infliximab non-response and being previously treated with an anti-tumor necrosis factor agent. Overall, around one fifth of adult patients require dose intensification and experience a loss of response after initiation of adalimumab therapy. Adalimumab dose escalation permits response to be regained in the majority of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationHanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationDignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Self-citationSandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Self-citationLoss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Gisbert, J. P., & Panés, J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.88 · Cited by 664
Peyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Self-citationKarmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Pancreatic Neuropathy and Neuropathic Pain—A Comprehensive Pathomorphological Study of 546 Cases
Ceyhan, G. O., Bergmann, F., Kadihasanoglu, M., Altintas, B., Demir, I. E., Hinz, U., Müller, M. W., Giese, T., Büchler, M. W., Giese, N. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.029 · Cited by 416
Romberg-Camps, M. J. L., Dagnelie, P. C., Kester, A. D. M., Hesselink-van de Kruijs, M. A. M., Cilissen, M., Engels, L. G. J. B., Van Deursen, C., Hameeteman, W. H. A., Wolters, F. L., Russel, M. G. V. M., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.38 · Cited by 286
Cited by
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
Optimizing anti-TNF treatments in inflammatory bowel disease
Ben-Horin, S., Kopylov, U., & Chowers, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.06.002 · Cited by 419
Bonaz, B., Sinniger, V., & Pellissier, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01452 · Cited by 405
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Nielsen, O. H., & Ainsworth, M. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmct1209614 · Cited by 334
Gisbert, J. P., Marín, A. C., McNicholl, A. G., & Chaparro, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13083 · Cited by 323
Yanai, H., Lichtenstein, L., Assa, A., Mazor, Y., Weiss, B., Levine, A., Ron, Y., Kopylov, U., Bujanover, Y., Rosenbach, Y., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.029 · Cited by 316
Ding, N. S., Hart, A., & De Cruz, P. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13445 · Cited by 309
New therapies for inflammatory bowel disease: from the bench to the bedside
Danese, S. (2012) · Gut · doi:10.1136/gutjnl-2011-300904 · Cited by 308
Dassopoulos, T., Sultan, S., Falck–Ytter, Y. T., Inadomi, J. M., & Hanauer, S. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.046 · Cited by 297
Anti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Gender differences in inflammatory bowel disease
Greuter, T., Manser, C., Pittet, V., Vavricka, S. R., Biedermann, L., & on behalf of Swiss IBDnet, A. O. W. G. O. T. S. S. O. G. (2020) · Digestion · doi:10.1159/000504701 · Cited by 198
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Self-citationUngar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13862 · Cited by 118
Prophylactic systemic P2X7 receptor blockade prevents experimental colitis
Marques, C. C., Castelo-Branco, M. T., Pacheco, R. G., Buongusto, F., do Rosário, A., Schanaider, A., Coutinho-Silva, R., & de Souza, H. S. P. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.012 · Cited by 78
Metadata
- Authors
- Billioud, V., Sandborn, W. J., & Peyrin-Biroulet, L.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-04
- Volume
- 106
- Issue
- 4
- Pages
- 674-684
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2030638161
- Cited by
- 433
- References
- 23
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.